McClellan’s Economic Background Could Influence FDA OTC Switch Policies
This article was originally published in The Tan Sheet
Executive Summary
Incoming FDA Commissioner Mark McClellan, MD/PhD, could have a "a high level of interest" in the issue of whether insurance firms may petition the agency to switch a drug OTC, according to CDER Office of Drug Evaluation V Director Jonca Bull, MD